Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis
Breast Cancer Research and Treatment · 2024-06 · 205 (2) · 403-411
DOI: 10.1007/s10549-024-07256-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 05.03.2024. Verfasst von Hongxia Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Unit 85, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Observer Variation, Immunohistochemistry. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The recent findings from the DESTINY-Breast04 trial highlighted the clinical importance of distinguishing between HER2 immunohistochemistry (IHC) scores 0 and 1 + in metastatic breast cancer (BC). However, pathologist interpretation of HER2 IHC scoring is subjective, and standardized methodology is needed. We evaluated the consistency of HER2 IHC scoring among pathologists and the accuracy of digital image analysis (DIA) in interpreting HER2 IHC staining in cases of HER2-low BC. METHODS: Fifty whole-slide biopsies of BC with HER2 IHC staining were evaluated, comprising 25 cases originally reported as IHC score 0 and 25 as 1 +. These slides were digitally scanned. Six pathologists with breast expertise independently reviewed and scored the scanned images, and DIA was applied. Agreement among pathologists and concordance between pathologist scores and DIA results were statistically analyzed using Kendall coefficient of concordance (W) tests. RESULTS: Substantial agreement among at least five of the six pathologists was found for 18 of the score 0 cases (72%) and 15 of the score 1 + cases (60%), indicating excellent interobserver agreement (W = 0.828). DIA scores were highly concordant with pathologist scores in 96% of cases (47/49), indicating excellent concordance (W = 0.959). CONCLUSION: Although breast subspecialty pathologists were relatively consistent in evaluating BC with HER2 IHC scores of 0 and 1 +, DIA may be a reliable supplementary tool to enhance the standardization and quantification of HER2 IHC assessment, especially in challenging cases where results may be ambiguous (i.e., scores 0-1 +). These findings hold promise for improving the accuracy and consistency of HER2 testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Unit 85, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA.
- School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Pathology, Unit 85, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA. asahin@mdanderson.org.
ORCID-Profile: Hongxia Sun, Hui Chen, Keith J Sweeney, Michael Suchko, Constance T Albarracin
Zitieren
APA
Sun, H., Kang, E. Y., Chen, H., Sweeney, K. J., Suchko, M., Wu, Y., Wen, J., Krishnamurthy, S., Albarracin, C. T., Ding, Q. Q., Foo, W. C., & Sahin, A. A. (2024). Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Research and Treatment, 205(2), 403-411. https://doi.org/10.1007/s10549-024-07256-3
Vancouver
Sun H, Kang EY, Chen H, Sweeney KJ, Suchko M, Wu Y, et al. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Research and Treatment. 2024;205(2):403-411. doi:10.1007/s10549-024-07256-3
BibTeX
@article{Sun2024,
author = {Sun, Hongxia and Kang, Eun Young and Chen, Hui and Sweeney, Keith J and Suchko, Michael and Wu, Yun and Wen, Jianguo and Krishnamurthy, Savitri and Albarracin, Constance T and Ding, Qing-Qing and Foo, Wai Chin and Sahin, Aysegul A},
title = {Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {205},
number = {2},
pages = {403--411},
doi = {10.1007/s10549-024-07256-3}
}
EUVIMED